Abstract
Relapsed/refractory medulloblastoma (MB) has a poor outcome regardless of the treatment employed. Novel therapies are needed in an effort to improve survivals. We present two children with recurrent/refractory MB treated with bevacizumab and irinotecan both given every 2 weeks. One patient also received temozolamide. The first patient had stable disease and remains without progression after 30 months. The second patient had a near complete response that was sustained for 18 months. The regimen was well tolerated with minimal toxicity and provided prolonged progression-free survival in these two patients. Prospective clinical trials are needed to evaluate the effectiveness of this strategy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 491-494 |
| Number of pages | 4 |
| Journal | Pediatric Blood and Cancer |
| Volume | 56 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2011 |
Keywords
- Bevacizumab
- Irinotecan
- Medulloblastoma
- Recurrent
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology